GlyNAC — a simple combination of the amino acids glycine and N-acetylcysteine (NAC) — has become one of the more intriguing longevity interventions of the decade, partly because its rationale is unusually straightforward. Older adults have dramatically lower levels of glutathione, the body's master intracellular antioxidant, and dramatically higher oxidative stress. Glutathione is synthesized from three amino acids (glycine, cysteine, and glutamate), and two of those — glycine and cysteine — become rate-limiting with age. Supplement the precursors, restore the glutathione, and oxidative damage should fall.
That's the hypothesis Rajagopal Sekhar and colleagues at Baylor College of Medicine have been testing for nearly two decades, culminating in a series of clinical trials in older adults and people aging with HIV. The results are provocative: improvements in muscle strength, walking speed, cognition, insulin sensitivity, and mitochondrial function after just 16 weeks. But the data come overwhelmingly from a single research group, replication is thin, and the scale is modest. This article walks through what the evidence actually supports.
What Is GlyNAC?
GlyNAC is not a branded drug. It is a supplement regimen combining two widely available amino acids:
- Glycine — the simplest amino acid and a direct precursor in glutathione biosynthesis.
- N-acetylcysteine (NAC) — an acetylated form of cysteine used clinically for decades as a mucolytic and as the antidote to acetaminophen overdose. NAC serves as the bioavailable source of cysteine, the limiting substrate in glutathione synthesis.
The logic is biochemical. Glutathione (GSH) is made in the cytosol of every cell by a two-step enzymatic reaction: glutamate and cysteine are joined by glutamate-cysteine ligase (the rate-limiting enzyme), then glycine is added by glutathione synthetase. In older adults, plasma and tissue glycine and cysteine concentrations fall, GSH synthesis rates drop, and intracellular GSH can be 30-40% lower than in young adults. At the same time, reactive oxygen species (ROS) production rises — largely from dysfunctional mitochondria — creating a widening gap between oxidant production and antioxidant capacity.
Sekhar's framing is that this imbalance is not a harmless consequence of aging but an upstream driver of mitochondrial dysfunction, insulin resistance, inflammation, and sarcopenia — several of the core hallmarks of aging.
The Science: Why Glutathione Matters
Glutathione is often described as the body's master antioxidant, but the label undersells its role. GSH:
- Directly scavenges free radicals including hydroxyl radicals and peroxynitrite.
- Serves as cofactor for glutathione peroxidases, which detoxify hydrogen peroxide and lipid peroxides.
- Regenerates vitamins C and E in their active reduced forms.
- Conjugates with xenobiotics in phase II detoxification.
- Regulates redox signaling through reversible S-glutathionylation of proteins, affecting everything from transcription factor activity to mitochondrial permeability.
Mitochondria are particularly dependent on GSH because they generate most cellular ROS as a byproduct of oxidative phosphorylation. Mitochondrial GSH depletion leads to proton leak, reduced ATP production, mitochondrial membrane damage, and eventually mitophagy failure or apoptosis. This ties GSH depletion directly to the mitochondrial dysfunction hallmark of aging.
Sekhar's earlier work in HIV patients (who experience accelerated aging phenotypes) established that GlyNAC supplementation could restore GSH synthesis rates, reduce oxidative stress markers (F2-isoprostanes, protein carbonyls), and improve mitochondrial bioenergetics. That foundation set up the older-adult trials.
The Evidence: The Key Trials
Kumar et al. 2021 (Clinical & Translational Medicine). This pilot open-label study gave eight older adults (ages 70-80) GlyNAC for 24 weeks at doses of 100 mg/kg/day glycine and 100 mg/kg/day NAC. Outcomes included GSH, oxidative stress markers, mitochondrial function, insulin resistance, inflammation, endothelial function, genotoxicity, muscle strength, gait speed, exercise capacity, and cognition. The results were striking across nearly all domains. But with eight participants and no control group, the study was hypothesis-generating rather than confirmatory.
Kumar et al. 2022 (Journal of Gerontology: Biological Sciences). This was the more rigorous follow-up: a 16-week randomized, placebo-controlled trial in 24 older adults. The GlyNAC group showed significant improvements versus placebo in:
- Red blood cell glutathione concentrations (restored toward young-adult levels)
- Markers of oxidative stress (F2-isoprostanes down, GSSG/GSH ratio improved)
- Mitochondrial fatty acid oxidation
- Insulin resistance (HOMA-IR improved)
- Inflammation markers (IL-6, TNF-alpha, hsCRP reduced)
- Gait speed and grip strength
- Six-minute walk distance
- Executive function on cognitive testing
Effect sizes were meaningful — gait speed and grip strength improvements in the range seen with structured exercise programs. Importantly, withdrawal of GlyNAC at week 16 led to reversion of many benefits at week 20, supporting a causal relationship.
HIV aging trials. Sekhar's group has run parallel studies in people living with HIV, who display premature aging phenotypes. Similar patterns emerged: restored GSH, improved mitochondrial function, better insulin sensitivity, and reduced oxidative stress. A 2020 trial in Biomedicines and subsequent papers have built this evidence base.
Current Clinical Status: Who's Working On This
Unlike many longevity interventions, GlyNAC is unusual in that the ingredients are cheap, off-patent, and widely available. There is no major pharmaceutical sponsor. The research is driven almost entirely by Sekhar's group at Baylor, with collaborations at other institutions.
Several ongoing and planned trials are extending the work:
- Larger RCTs in older adults are underway to confirm the 2022 findings with bigger sample sizes and longer durations.
- Trials in metabolic disease (type 2 diabetes, NAFLD) are testing whether GlyNAC benefits translate to disease-modification endpoints.
- GlyNAC in neurodegeneration — pilot studies in mild cognitive impairment and Alzheimer's risk populations.
- Commercial formulations. Several supplement brands now sell pre-mixed GlyNAC products, though dosing is often sub-therapeutic relative to the trial protocols (which used around 100 mg/kg/day of each, or roughly 7-8 grams daily of each amino acid for a 70 kg adult).
The field has not seen a large pharma-funded pivotal trial, which is both a feature (no commercial bias) and a bug (no deep pockets to run definitive studies).
Connection to Gene Editing & Peptides
GlyNAC sits in a broader longevity-intervention ecosystem that increasingly intersects with gene editing and peptide biology.
- Mitochondrial health overlap. GlyNAC's mitochondrial effects parallel those proposed for MOTS-c, the mitochondrial peptide — both aim to rescue bioenergetic decline in aged cells. A logical question for future trials is whether these interventions stack.
- Peptide context. GlyNAC is not a peptide (peptides are chains of amino acids linked by peptide bonds; GlyNAC is two free amino acids), but it belongs to the same "small molecule / amino-acid biology" family that longevity peptides operate within.
- Gene-editing angle. Could you edit genes involved in glutathione synthesis (for example, glutamate-cysteine ligase modifier subunit, GCLM) to restore youthful GSH capacity directly? In principle yes — base editing could introduce gain-of-function variants — but this is speculative. Supplementing precursors is vastly simpler and reversible.
Limitations
A balanced view of GlyNAC requires acknowledging several concerns:
- Single-group problem. Almost all human data come from Sekhar's lab at Baylor. Independent replication at scale has not yet been published.
- Small samples. The definitive 2022 RCT had 24 participants. Longevity interventions need larger, longer, multi-center trials before strong claims are warranted.
- Open-label and biomarker-heavy. Some of the most striking early data came from open-label studies where expectation effects can inflate subjective measures.
- Dose. Trial doses are substantial (several grams of each amino acid daily) and not matched by most commercial supplements.
- NAC regulatory status. In the U.S., the FDA has periodically asserted that NAC is a drug rather than a supplement, creating regulatory uncertainty.
- Safety at high doses. Both glycine and NAC are generally well-tolerated, but long-term safety at therapeutic doses is not fully characterized. NAC can cause GI upset and rare hypersensitivity reactions.
- Mechanism vs outcome. Restoring glutathione is biologically attractive, but decades of antioxidant trials (vitamin E, beta-carotene) have shown that crude "reduce oxidative stress" strategies often fail to deliver clinical benefit. GlyNAC's specificity to precursor-limited glutathione synthesis is its best argument for being different.
FAQ
Is GlyNAC the same as taking a glutathione supplement?
No. Oral glutathione is largely degraded in the GI tract and has poor bioavailability. GlyNAC instead supplies the rate-limiting precursors, allowing cells to synthesize their own GSH where it's needed.
What dose did the trials use?
Roughly 100 mg/kg/day of glycine and 100 mg/kg/day of NAC, split into two doses. For a 70 kg adult that's about 7 grams of glycine and 7 grams of NAC daily.
Is GlyNAC safe?
Short-term safety in the trials was good. Glycine is a dietary amino acid; NAC has decades of clinical use. GI upset is the most common side effect. Long-term safety at high doses in healthy older adults is still being characterized.
Does GlyNAC lower biological age?
Some markers of mitochondrial and oxidative stress improve, and small studies have reported directional changes in epigenetic clock estimates, but no well-powered RCT has demonstrated biological-age reversal as a primary endpoint.
How does GlyNAC compare to NAC alone?
Sekhar's data suggest the combination outperforms either component, because both glycine and cysteine become rate-limiting in older adults. NAC alone doesn't fully restore GSH synthesis in that context.
Could you just eat more protein?
Dietary protein contains glycine and cysteine, but typical diets supply amounts far below the trial doses, and cysteine from food is less bioavailable than NAC. Whey protein is glycine-poor; collagen is glycine-rich but cysteine-poor.
Further Learning
- Hallmarks of Aging Explained — how oxidative and mitochondrial decline fit the framework
- MOTS-c: The Mitochondrial Peptide and Aging — a complementary mitochondrial intervention
- Peptides for Longevity: A Beginner's Guide — the broader peptide landscape
